Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06758596 · ClinicalTrials.gov registry record · Early Phase 1
Research Investigating Drug Effects-2 (RiDE-2)
A Early Phase 1 study, sponsored by University of Illinois at Chicago.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 144
- Enrollment target
NCT06758596: Clinical Trial Early Phase 1 study, sponsored by University of Illinois at Chicago.
NCT06758596 is a Early Phase 1 study that has not yet begun recruiting, run by University of Illinois at Chicago. The registered enrollment target is 144 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (172% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06758596, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Illinois at Chicago.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs. We are also trying to understand why some people may feel differently or their brain may respond differently than other people after taking the same recreational drug.
Primary Outcome
Participants will complete the 6-month Timeline Follow-Back (TLFB) and Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU) to assess recent substance use. This measure will capture the frequency of substance use during the past 6 months, with greater values indicating more frequent substance use.
Interventions
- DRUG THC
- DRUG Placebo Oral Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2031-06 |
| Phase | Early Phase 1 |
What is known before NCT06758596 opens enrollment
NCT06758596 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (172% higher).
The record links to 0 conditions, and to 2 interventions - of which THC is the first listed.
NCT06758596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06758596 about?
NCT06758596 is a clinical study titled "Research Investigating Drug Effects-2 (RiDE-2)". The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs. We are also trying to understand why some people may feel differently or their brain may respond differently than other people after taking the same recreational drug.
What is the current status of trial NCT06758596?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 144 participants. The study started on 2026-07-15. Estimated completion is 2031-06.
What interventions are being tested in trial NCT06758596?
The interventions under investigation include: THC (DRUG), Placebo Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT06758596?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06758596's enrollment target sits among peer trials
144 110th of 2000 higher than 1,889 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI